JP6860267B2 - アゼチジン誘導体、その調製方法、及びその使用 - Google Patents

アゼチジン誘導体、その調製方法、及びその使用 Download PDF

Info

Publication number
JP6860267B2
JP6860267B2 JP2018518690A JP2018518690A JP6860267B2 JP 6860267 B2 JP6860267 B2 JP 6860267B2 JP 2018518690 A JP2018518690 A JP 2018518690A JP 2018518690 A JP2018518690 A JP 2018518690A JP 6860267 B2 JP6860267 B2 JP 6860267B2
Authority
JP
Japan
Prior art keywords
reaction
compound
azetidine
mmol
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018518690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536634A (ja
JP2018536634A5 (enExample
Inventor
イノン シェ，
イノン シェ，
ゼジン ユウ，
ゼジン ユウ，
ジィウェン デン，
ジィウェン デン，
ジュン ジュウ，
ジュン ジュウ，
アオ ワン，
アオ ワン，
イェン フェン，
イェン フェン，
ドン ロン，
ドン ロン，
フン ツェン，
フン ツェン，
フンメイ ソン，
フンメイ ソン，
チジュン イェ，
チジュン イェ，
ウェイ チィ，
ウェイ チィ，
ドンハイ スー，
ドンハイ スー，
リチュン ワン，
リチュン ワン，
ジンイ ワン，
ジンイ ワン，
Original Assignee
シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド
シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド, シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド filed Critical シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド
Publication of JP2018536634A publication Critical patent/JP2018536634A/ja
Publication of JP2018536634A5 publication Critical patent/JP2018536634A5/ja
Application granted granted Critical
Publication of JP6860267B2 publication Critical patent/JP6860267B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018518690A 2015-12-11 2016-12-08 アゼチジン誘導体、その調製方法、及びその使用 Active JP6860267B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510924946 2015-12-11
CN201510924946.1 2015-12-11
PCT/CN2016/109036 WO2017097224A1 (zh) 2015-12-11 2016-12-08 氮杂环丁烷衍生物、其制备方法及用途

Publications (3)

Publication Number Publication Date
JP2018536634A JP2018536634A (ja) 2018-12-13
JP2018536634A5 JP2018536634A5 (enExample) 2019-12-19
JP6860267B2 true JP6860267B2 (ja) 2021-04-14

Family

ID=59012693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518690A Active JP6860267B2 (ja) 2015-12-11 2016-12-08 アゼチジン誘導体、その調製方法、及びその使用

Country Status (8)

Country Link
US (3) US10159662B2 (enExample)
EP (1) EP3360878B9 (enExample)
JP (1) JP6860267B2 (enExample)
CN (1) CN108137603B (enExample)
DK (1) DK3360878T3 (enExample)
ES (1) ES2830446T3 (enExample)
HK (1) HK1250707B (enExample)
WO (1) WO2017097224A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1250707B (zh) * 2015-12-11 2020-07-03 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物、其制备方法及用途
EP3572415B1 (en) * 2017-01-23 2024-03-06 Shanghai Longwood Biopharmaceuticals Co., Ltd. Jak kinase inhibitor and preparation method and use thereof
ES2937823T3 (es) 2017-06-07 2023-03-31 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Forma sólida del derivado de azetidina y método de preparación del mismo y uso del mismo
SG11202002947TA (en) 2017-11-03 2020-04-29 Aclaris Therapeutics Inc Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
CN113149993A (zh) * 2017-12-01 2021-07-23 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
AR117398A1 (es) * 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
BR112021002479A2 (pt) 2018-08-10 2021-07-27 Aclaris Therapeutics, Inc. composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN111518096B (zh) * 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
WO2020173364A1 (zh) * 2019-02-27 2020-09-03 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020256720B2 (en) 2019-04-12 2022-09-01 PrimeGene (Beijing) Co. Ltd. Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
CN113727975A (zh) 2019-05-02 2021-11-30 阿克拉瑞斯治疗股份有限公司 作为jak抑制剂的被取代的吡咯并吡啶
CN110028432A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种（3-氨基-氮杂环丁烷-1-基）-环丙基-甲酮的制备方法
CA3141571A1 (en) * 2019-05-28 2020-12-03 Mankind Pharma Ltd. 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2025509642A (ja) 2022-03-18 2025-04-11 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド アゼチジン誘導体の使用および治療方法
WO2023226822A1 (zh) * 2022-05-26 2023-11-30 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物治疗病毒感染的方法及用途
CN115974864B (zh) * 2022-12-29 2025-09-16 苏州汉德创宏生化科技有限公司 一种2-(3-氮杂环丁基)噻唑盐的合成方法
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
CN120530118A (zh) * 2023-01-18 2025-08-22 北京普祺医药科技股份有限公司 一种氮杂环烷烃化合物、药物组合物及其用途
CN116444529B (zh) * 2023-06-16 2023-12-05 药康众拓(江苏)医药科技有限公司 一种氘代氮杂环丁烷类jak抑制剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380795T3 (es) 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
ES2602577T3 (es) * 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
SMT201800137T1 (it) 2010-03-10 2018-07-17 Incyte Holdings Corp Derivati di piperidin-4-il azetidina come inibitori di jak1
WO2012177606A1 (en) * 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MA39984B1 (fr) 2014-04-08 2020-12-31 Incyte Corp Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
HK1250707B (zh) * 2015-12-11 2020-07-03 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物、其制备方法及用途

Also Published As

Publication number Publication date
JP2018536634A (ja) 2018-12-13
US10159662B2 (en) 2018-12-25
CN108137603A (zh) 2018-06-08
CN108137603B (zh) 2019-10-18
EP3360878B1 (en) 2020-09-16
DK3360878T3 (da) 2020-11-09
EP3360878B9 (en) 2021-05-05
HK1250707B (zh) 2020-07-03
US20190060291A1 (en) 2019-02-28
HK1251551A1 (en) 2019-02-01
US20180289680A1 (en) 2018-10-11
EP3360878A4 (en) 2019-03-06
WO2017097224A1 (zh) 2017-06-15
EP3360878A1 (en) 2018-08-15
US11045455B2 (en) 2021-06-29
ES2830446T3 (es) 2021-06-03
US20200147062A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP6860267B2 (ja) アゼチジン誘導体、その調製方法、及びその使用
CN111315747B (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
JP6600365B2 (ja) Ｊａｋ阻害剤
CN101048406B (zh) 新型取代的咪唑衍生物
JP6867417B2 (ja) キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
KR20220061958A (ko) Cd38의 억제제로서의 헤테로바이사이클릭 아미드
HK1250707A1 (en) Azetidine derivative, preparation method therefor, and use thereof
JP7547387B2 (ja) ＮＦ－κＢ誘導キナーゼの低分子阻害剤
WO2011028685A1 (en) Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR102412035B1 (ko) TGF-βRI 억제제인 벤조트리아졸에서 유도된 α,β-불포화 아미드계 화합물
KR20140019300A (ko) Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
EA012873B1 (ru) 6,6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
KR20140076619A (ko) 5,7-치환된-이미다조[1,2-c]피리미딘
CN109790158B (zh) 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
AU2023254866B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
TW201639845A (zh) 新的雜芳基和雜環化合物、其組成物及方法
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
TW202204351A (zh) 具有大環結構的化合物及其用途
CN116925077A (zh) 吡啶并环类化合物及其制备方法、中间体、组合物和应用
TW202313035A (zh) Ｊａｋ２抑制劑及其使用方法
CN112209934B (zh) 含有氮杂螺庚烷的btk抑制剂
HK1251551B (en) Azetidine derivative, preparation method therefor, and use thereof
HK40004455B (en) Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210323

R150 Certificate of patent or registration of utility model

Ref document number: 6860267

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250